Drug Trial Radar · NCT01216865
Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot
Last checked: Nov 20, 2026Latest source record: Oct 13, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Jan 2011
Primary completion
Dec 2012
Study completion Jul 2013
Sponsor
- Lead sponsor
- Qingdao UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 7, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether umbilical cord Mesenchymal Stem Cells of treatment for diabetic foot is safe and effective in the management of diabetic foot ischemia, the therapeutic effect of stem cells is caused by improving blood circulation in ischemic limb which would in turn promote ulcer healing, prevent amputation of limb and relieve the Sevier pain of ischemia.
Conditions
- Diabetic Foot
- Critical Limb Ischemia
- Mesenchymal Stem Cells
- Umbilical Cord
Interventions
umbilical cord mesenchymal stem cellsBiological
5\*10/7 per ischemic limb
Standard TherapyDrug
Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
Primary outcomes
What the sponsor says the trial is designed to measure.
- Angiographic evaluation of angiogenesis at ischemic limbTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stem Cell Research Center of Medical School Hospital of Qingdao University
Qingdao, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.